http://jmbiotech.tradekorea.com
JMB is a specialty venture corporate dedicated to the product development (R&D), manufacturing and overseas business of innovative quality healthcare products forphysicians and patients across the world. JMB was founded with the goal of establishing biotech company exclusively focused on following five specific healthcare related areas; -Innovative skin stimulating medical device, TurtlePin®-Cosmeceuticals-Medi-aesthetic therapy-Nutraceutical supplements-Consumer care (BtoC brand managment)
JM Biotech Corporation Limited is a R&D, manufacturing and overseas sales specialist subsidiary of Jeilmedix Pharmaceutical Corporation.
JMB was incorporated as an independent business unit in 2013 in order to satisfy the increasing demand for specialist R&D and overseas distribution, in addition to providing cutting-edge Cosmeceutical and Nutraceutical products as well as the supply of high-quality medical devices (notably the sterile direct dermal injecting devices, TurtlePin ®). In addition, JMB supplies overseas clients with raw materials for solutions, including Peptides and Growth Factors.
Prior to the emergence of JM Biotech Co., since 1999 the Jeilmedix pharmaceutical has been active in striving for international patents for a variety of high-quality medical instruments and products, whilst maintaining Jeilmedix Pharmaceutical Co.’s leading edge in the Korean pharmaceutical, Nutraceutical, Cosmeceutical and aesthetic markets. We continue to define our success by our responsiveness to our clients’ specific needs and aspirations rather than certain trends in the market.
With 16 years of experience in the field, recently in 2013 JM Biotech acquired international patents for 5th-generation painless microneedle direct dermal injecting devices under the TurtlePin ® and Belluspin ® signature series label. In addition, our highly effective Peptide and Growth Factor solutions such as TurtlePin ® HL, Belluspin ® A50, Belluspin ® W30, Belluspin ® H40 are at the core of our world-class export product line.
JM Biotech Corporation Limited is a R&D, manufacturing and overseas sales specialist subsidiary of Jeilmedix Pharmaceutical Corporation.
JMB was incorporated as an independent business unit in 2013 in order to satisfy the increasing demand for specialist R&D and overseas distribution, in addition to providing cutting-edge Cosmeceutical and Nutraceutical products as well as the supply of high-quality medical devices (notably the sterile direct dermal injecting devices, TurtlePin ®). In addition, JMB supplies overseas clients with raw materials for solutions, including Peptides and Growth Factors.
Prior to the emergence of JM Biotech Co., since 1999 the Jeilmedix pharmaceutical has been active in striving for international patents for a variety of high-quality medical instruments and products, whilst maintaining Jeilmedix Pharmaceutical Co.’s leading edge in the Korean pharmaceutical, Nutraceutical, Cosmeceutical and aesthetic markets. We continue to define our success by our responsiveness to our clients’ specific needs and aspirations rather than certain trends in the market.
With 16 years of experience in the field, recently in 2013 JM Biotech acquired international patents for 5th-generation painless microneedle direct dermal injecting devices under the TurtlePin ® and Belluspin ® signature series label. In addition, our highly effective Peptide and Growth Factor solutions such as TurtlePin ® HL, Belluspin ® A50, Belluspin ® W30, Belluspin ® H40 are at the core of our world-class export product line.
